News

Nasdaq20d
Clearmind Medicine Inc. Announces Arrival of CMND-100 in the U.S. Ahead of Phase I/IIa Trial for Alcohol Use Disorder
Clearmind Medicine announces arrival of CMND-100 in the U.S. for Phase I/IIa trial targeting Alcohol Use Disorder treatment. Clearmind Medicine Inc., a clinical-stage biotech company, announced ...
Yahoo Finance21d
Clearmind Medicine’s FDA-Approved Clinical Trial for CMND-100 Moves Forward as Drug Arrives in the U.S., Advancing Toward Key Milestones
Clearmind Medicine Inc. Vancouver, Canada, March 21, 2025 (GLOBE NEWSWIRE) -- Clearmind Medicine Inc. (Nasdaq: CMND), (FSE: CWY0) (“Clearmind” or the "Company"), a clinical-stage biotech ...
Nasdaq23d
Clearmind Medicine Initiates First Clinical Trial Of CMND-100 For Alcohol Use Disorder Treatment
(RTTNews) - Clearmind Medicine Inc.(CMND), Tuesday announced the initiation of its Phase I/IIa clinical trial to investigate the safety, tolerability, and pharmacokinetics of its innovative drug ...
Yahoo Finance24d
Clearmind Medicine Announces Initiation of First in Human Clinical Trial with CMND-100 in Alcohol Use Disorder Patients
Study represents the first clinical application of CMND-100, the Company’s proprietary drug platform Vancouver, Canada, March 18, 2025 (GLOBE NEWSWIRE) -- Clearmind Medicine Inc. (Nasdaq ...
Wall Street Journal2y
Clearmind Medicine Inc.
The Price to Earnings (P/E) ratio, a key valuation measure, is calculated by dividing the stock's most recent closing price by the sum of the diluted earnings per share from continuing operations ...